Study #2025-0836
A phase 1b/2a, multicenter, open-label study to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of Mezigdomide in combination with Elranatamab in participants with relapsed and/or refractory multiple myeloma
MD Anderson Study Status
Enrolling
Treatment Agent
Elranatamab, Mezigdomide, Dexamethasone
Description
The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Multiple Myeloma
Study phase:
Physician name:
Jing Ye
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.?